CD38 and plasma cell myeloma: Daratumumab binds specifically to the CD38+ antigenic epitopes on myeloma cells, exerting anti-myeloma effects through mechanisms such as antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, direct induction of apoptosis, and inhibition of intrinsic CD38+ enzymatic activity (26).